A5044057983- Diagnosis and Treatment of Venous Diseases
- Venous Thromboembolism Diagnosis and Management
- Pituitary Gland Disorders and Treatments
- Intracranial Aneurysms: Treatment and Complications
- Glioma Diagnosis and Treatment
- Mosquito-borne diseases and control
- Thermoregulation and physiological responses
- Peripheral Artery Disease Management
- Cerebrovascular and Carotid Artery Diseases
- Traumatic Brain Injury and Neurovascular Disturbances
- Diabetic Foot Ulcer Assessment and Management
- Insect symbiosis and bacterial influences
- Entomological Studies and Ecology
- Cerebrospinal fluid and hydrocephalus
- Vascular Malformations Diagnosis and Treatment
- Botulinum Toxin and Related Neurological Disorders
- Central Venous Catheters and Hemodialysis
- Peroxisome Proliferator-Activated Receptors
- Craniofacial Disorders and Treatments
- Restless Legs Syndrome Research
- Fetal and Pediatric Neurological Disorders
- Travel-related health issues
- Climate Change and Health Impacts
- Antioxidant Activity and Oxidative Stress
- Laser Applications in Dentistry and Medicine
University of Neuchâtel
2023-2024
University of Pisa
2003-2009
University of Chieti-Pescara
1985-2007
University of L'Aquila
2006
St Mary's Hospital
2002-2003
Ealing Hospital
2002-2003
St. Mary's Hospital
2002-2003
Imperial College London
2002-2003
St Mary's Hospital
2003
Monash Medical Centre
2003
The study compared, by a prospective, randomized method, 6 treatment options: A: Sclerotherapy; B: High-dose sclerotherapy; C: Multiple ligations; D: Stab avulsion; E: Foam-sclerotherapy; F: Surgery (ligation) followed sclerotherapy. Results were analyzed 10 years after inclusion and initial treatment. Endpoints of the variations in ambulatory venous pressure (AVP), refilling time (RT), presence duplex-reflux, number recurrent or new incompetent sites. patients, limbs, treated segments...
Cerebral microembolism has often been documented by transcranial Doppler imaging during carotid angioplasty and stenting. However, few data are available about its characteristics the 2 different kinds of procedure.To compare incidence microemboli occurring alone with that stenting in phases procedures to relate it periprocedural cerebrovascular complications.Thirty-eight patients underwent 41 (15 26 stenting) for symptomatic stenoses 70% or more. Transcranial monitoring was performed detect...
The aim of this study was to evaluate the development edema, and superficial deep vein thrombosis (DVT) prophylaxis with an oral profibrinolytic agent (Flite Tabs, 150 mg pinokinase, Aidan, Tempe, AZ, USA) in long-haul flights (7-8 hours), high-risk subjects. A group 300 subjects included; 76 were excluded for several problems including concomitant treat ments ; 204 randomized into 2 groups (active treatment or placebo) effects Flite Tabs. An exercise program used both groups. femoral,...
OBJECTIVE: The objective of the study was to evaluate expression and functional activity Peroxisome proliferator-activated receptor (PPAR) gamma in pituitary adenomas from 14 consecutive acromegalic patients establish its role apoptosis. SUBJECTS AND METHODS: Fourteen were enrolled study. Wistar-Furth rats used for vivo studies. Expression PPARgamma evaluated by RT-PCR Western blot. Apoptosis cell cycle assessed FACS analysis. effects ligands on transcriptional regulation GH gene...
The aim of this study was to investigate the clinical efficacy oral Pycnogenol® (Horphag Research Ltd., UK) in patients with severe chronic venous insufficiency (CVI) comparison combination diosmin and hesperidin (Daflon®, Servier, France). A group 86 (CVI), hypertension, ankle swelling) previous history ulcerations received either Pycnogenol (capsules) 150 mg or 300 daily for 8 weeks Daflon, 1000 mg/day. All completed without dropouts. At end study, microcirculatory results indicated: a...
The aim of this independent study was to investigate differences in efficacy between oxerutins (Venoruton) and 500 mg micronized diosmin + hesperidin (D+H) (Daflon) patients with chronic venous insufficiency (CVI), evaluating venous-related quality life (Ve-QOL). A first group 90 severe hypertension (CVI, ankle swelling) randomized treatment or D+H. received oral (2 g/day); the D+H 3 (500 mg) tablets daily every 8 hours for weeks. second 122 comparable included a registry following same...
Superficial vein thrombosis is characterized by clotting of superficial veins (ie, following direct trauma) with minimal inflammatory components. thrombophlebitis a minimally thrombotic process associated changes and/or infection. Treatments generally include analgesics, elastic compression, anti-inflammatory agents, exercise and ambulation, and, in some cases, local or systemic anticoagulants. It better to avoid bed rest reduced mobility. Topical analgesia nonsteroidal, creams applied...
The aim of this study was to investigate the clinical efficacy oral Pycnogenol ® (Horphag Research Ltd, United Kingdom) in patients with diabetic microangiopathy. Patients without a history ulcerations were treated Pycnogenol. received (50 mg capsules, 3 times daily for total 150 4 weeks). A group 30 included (severe microangiopathy); comparable observed as controls (no treatment during observation period). All (age, 59 years; range, 55-68 male:female = 18:12) completed 4-week study. Also,...
The aim of this study was to evaluate deep venous thrombosis (DVT) prophylaxis with specific elastic stockings in longhaul flights (11-13 hours), high-risk subjects. A group 300 subjects included; 76 were excluded for several problems including concomitant treatments; 224 randomized into two groups (stockings vs. controls) below-knee stockings. An exercise program used both groups. Scholl (UK) Flight Socks (14-17 mmHg pressure at the ankle) used. DVT diagnosed ultrasound scanning. femoral,...
The aim of this study was to evaluate the occurrence deep venous thrombosis (DVT) and superficial vein (SVT) its prophylaxis with an oral anti-edema antithrombotic agent (Pycnogenol ® , Horphag, Research Management SA, Geneva, Switzerland) in long-haul flights, subjects at moderate high-risk DVT SVT. pre-included 244 pre-selected subjects; 211 were included (33 excluded for several reasons due logistic problems) 198 completed study; 13 lost follow-up end flight, all non-medical problems...
The aim of this study was to investigate the clinical efficacy oral Pycnogenol® (Horphag Research Ltd, UK) in patients with severe chronic venous insufficiency. Patients hypertension (chronic insufficiency, ankle swelling) and history ulcerations were treated Pycnogenol. received Pycnogenol (50 mg capsules, 3 times daily for a total 150 daily) 8 weeks. A group 21 included treatment 18 equivalent observed as controls (no during observation period). All (age 53 years; range, 42-60 M:F=11:10)...
The aim of this study was to assess the preventive action Pycnogenol® (Horphag Research Ltd, UK) on cramps and muscular pain in different groups subjects patients. included a 5-week observation period (4 weeks treatment one follow-up week after suspension treatment) evaluate efficacy Pycnogenol its withdrawal. Four 50 mg capsules (total dose 200 mg/day) were prescribed with suggestion drink at least 1.5 liters water every day. In first part 66 healthy completed period. difference between...
The aim of this study was to evaluate the prevention recurrent deep vein thrombosis (RDVT) with an oral antithrombotic agent (sulodexide) in moderate high-risk subjects. A group 405 patients included into multicenter registry. Both compression and exercise program were used as well a risk-factors control plan. After diagnosis DVT, treated anticoagulants for 6 months. At end period coagulation made started treatment sulodexide capsules 24 femoral, popliteal, tibial, superficial veins scanned...
The aim of this independent study was to demonstrate the rapidity clinical action HR 0-(beta-hydroxyethyl)-rutosides, Venoruton ® (Novartis Consumer Health) in patients with chronic venous insufficiency (CVI). Two groups hypertension and microangiopathy were treated (1 or 2 g/day, for 8 weeks). Twelve (age 56.4; range 44-66; M:F = 6:6) included group 1 g/day) (moderate CVI microangiopathy); 10 57.4; 42-67; 5:5) (2 more severe microangiopathy. Average ambulatory pressure (AVP) 58.6 (range...
The aim of this study was to evaluate the prevention edema during long-haul flights with an oral, anti-edema and antithrombotic agent (Pycnogenol ® , Horphag, Research Management SA, Geneva, Switzerland) in asymptomatic subjects. assessment performed by evaluating analogue scale, rate ankle swelling strain-gauge derived (RAS), assessing circumference variation. included 211 subjects; 169 completed (88 control group 81 Pycnogenol group). There were no important differences between two groups...
Shock waves (SW) are used to control pain in different clinical conditions (eg, painful knee, elbow, and shoulder, etc). The effects of SWs may be due cellular ;;stunning'' (particularly nervous components). It also the consequence unknown metabolic actions on tissues, which include changes permeability, liberation proteins mediators locally acting nerve endings. aim this study was evaluate reduction improvement microcirculation induced by SW treatment a 2-week patients with chronic limb...
The aim of this study was to demonstrate whether HR (Paroven-Venoruton; 0-(β-hydroxyethyl)-rutosides), effective in improving the microcirculation venous hypertension and microangiopathy. Sixty patients with severe due chronic insufficiency, ankle swelling, lipodermatosclerosis were included. After informed consent, randomized into a treatment group placebo group. Patients received oral (2 g/day for 8 weeks); those comparable placebo. Results: two groups age sex distribution. mean 45 years...
The aim of this study was to demonstrate whether HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides), effective in improving levels plasma free radicals (PFRs) patients with chronic venous insufficiency (CVI) and microangiopathy. Patients were randomized into the treatment group, which received oral (1g sachets, twice daily, for 4 weeks), a placebo comparable placebo. Below-knee Sigvaris stockings used during study. PFRs measured D-Rom test at finger vein leg an area CVI. mean age...
This study was planned to demonstrate in a prospective, placebo-controlled, randomized study, whether HR (Paroven, Venoruton; 0-(P-hydroxyethyl)-rutosides), is effective improving the microcirculation subjects with diabetic microangiopathy and neuropathy. Patients severe microangiopathy, neuropathy edema, patients without neuropathy, 20 healthy were included. Microangiopathy defined by laser Doppler flowmetry capillary filtration (rate of ankle swelling (RAS)). Inclusion criteria were:...
The variation of capillary filtration rate (CFR) and ankle edema (AE) were evaluated in three groups patients with venous hypertension ambulatory pressure > 42 mmHg healthy subjects before after treatment for four weeks HR (Paroven, Venoruton; 0-(P-hydroxyethyl)-rutosides), a venoactive drug acting on the microcirculation permeability. Group A (30 patients) was treated 500 mg tid; group B 1 g C placebo; D (10 subjects) g/day randomised study. CFR assessed by occlusion plethysmography....
Objectives: The aim of this study was to demonstrate whether and how HR (Venoruton 1000 , Paroven, 0-[beta-hydroxyethyl]-rutosides) Daflon (diosmin, 500 mg) were comparatively effective in improving the microcirculation venous hypertension microangiopathy. Methods: A group 90 patients with severe due chronic insufficiency, ankle swelling, lipodermatosclerosis included. After informed consent, randomized into a Venoruton (DF) group: received oral (2 g/day for 8 weeks); those three 500-mg...